Strategies for treating and managing chronic hepatitis C in children in the direct-acting antiviral era
Authors:
Open Access
- 15 February 2020
- journal article
- editorial
- Published by Korean Pediatric Society in Clinical and Experimental Pediatrics
- Vol. 63 (2) , 46-47
Abstract
No abstract availableThis publication has 7 references indexed in Scilit:
- Thyroid disturbances in children treated with combined pegylated interferon-alpha and ribavirin for chronic hepatitis CClinical and Experimental Pediatrics, 2020
- EASL Recommendations on Treatment of Hepatitis C 2018Journal of Hepatology, 2018
- Direct-acting antivirals for children and adolescents with chronic hepatitis CThe Lancet Child & Adolescent Health, 2018
- Current status of and strategies for hepatitis C control in South KoreaClinical and Molecular Hepatology, 2017
- Incidence of and risk factors for thyroid dysfunction during peginterferon α and ribavirin treatment in patients with chronic hepatitis CThe Korean Journal of Internal Medicine, 2015
- High sustained virologic response rates in children with chronic hepatitis C receiving peginterferon alfa-2b plus ribavirinJournal of Hepatology, 2010
- The clinical and physiological spectrum of interferon‐alpha induced thyroiditisHepatology, 2006